@article{2c298facc0b74916bf863da603ca9e6c,
title = "Consensus Statement on Inpatient Use of Continuous Glucose Monitoring",
abstract = "In June 2016, Diabetes Technology Society convened a panel of US experts in inpatient diabetes management to discuss the current and potential role of continuous glucose monitoring (CGM) in the hospital. This discussion combined with a literature review was a follow-up to a meeting, which took place in May 2015. The panel reviewed evidence on use of CGM in 3 potential inpatient scenarios: (1) the intensive care unit (ICU), (2) non-ICU, and (3) transitioning outpatient CGM use into the hospital setting. Panel members agreed that data from limited studies and theoretical considerations suggested that use of CGM in the hospital had the potential to improve patient clinical outcomes, and in particular reduction of hypoglycemia. Panel members discussed barriers to widespread adoption of CGM, which patients would benefit most from use of this technology, and what type of outcome studies are needed to guide use of CGM in the inpatient setting.",
keywords = "continuous glucose monitor, diabetes, glucose, hospital, hypoglycemia, inpatient",
author = "Amisha Wallia and Umpierrez, {Guillermo E.} and Rushakoff, {Robert J.} and Klonoff, {David C.} and Rubin, {Daniel J.} and {Hill Golden}, Sherita and Cook, {Curtiss B.} and Bithika Thompson",
note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Amisha Wallia is a consultant for Glytec, a research investigator for Eli Lilly, a research investigator for Merck, and a trial adjudicator for Lexicon. Guillermo Umpierrez has received research funds (to Emory University) from Sanofi, Novo Nordisk, Merck, Astra Zeneca, and Boehringer Ingelheim, and has received consultant honorarium from Sanofi. Robert Rushakoff has no disclosures. David Klonoff is a consultant for Insulet, LifeCare, and Voluntis. Daniel Rubin has received research grants from Merck, AstraZeneca, and Boehringer Ingelheim. Sherita Hill Golden has no disclosures. Curtiss Cook has no disclosures. Bithika Thompson has no disclosures. Saleh Adi is consultant for Insulet, Dexcom, and NovoNordisk, Board member and advisor for Tidepool. Elizabeth Buschur has no disclosures. Jessica Castle has a significant financial interest in Pacific Diabetes Technologies, Inc, a company that may have a commercial interest in the results of this research and technology. This potential conflict of interest has been reviewed and managed by OHSU. Eda Cengiz received a study equipment grant from Dexcom and Medtronic for investigator initiated research. Boris Draznin has no disclosures. Andrew Drexler has no disclosures. Andjela Drincic has no disclosures. Kathleen Dungan has no disclosures. Roma Gianchandani has no disclosures. Janice Gilden has no disclosures. Victoria C. Hsiao has no disclosures. Kristen Kulasa has no disclosures. Lillian F. Lien has done consulting for Merck, Eli Lilly, Novo Nordisk, and Sanofi. Michelle Magee has no disclosures. Irina Nayberg has no disclosures. Henry Rodriguez has no disclosures. Archana Sadhu has no disclosures. Andrea Stallings has no disclosures. Cecilia C. Low Wang has no disclosures. Publisher Copyright: {\textcopyright} 2016 Diabetes Technology Society.",
year = "2017",
month = sep,
day = "1",
doi = "10.1177/1932296817706151",
language = "English (US)",
volume = "11",
pages = "1036--1044",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "5",
}
